In this article:

Dawson James Remains a Hold on Caladrius Biosciences (CLBS)

In this article:
In this article:

Dawson James analyst Jason Kolbert maintained a Hold rating on Caladrius Biosciences (CLBSResearch Report) on December 10. The company’s shares closed last Tuesday at $1.03, close to its 52-week low of $0.82.

According to TipRanks.com, Kolbert ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.

The the analyst consensus on Caladrius Biosciences is currently a Hold rating.

See the top stocks recommended by analysts >>

Based on Caladrius Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.93 million. In comparison, last year the company had a GAAP net loss of $5.33 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Read More on CLBS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed